NCT06763835View on ClinicalTrials.gov

Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis

Active, not recruitingOBSERVATIONAL
Enrollment

301

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

July 30, 2024

Study Completion Date

July 30, 2026

Conditions
Plaque RuptureAcute Coronary Syndromes
Interventions
DIAGNOSTIC_TEST

Blood is drawn to test for specific biomarkers

After identifying characteristic biomarkers that can distinguish between PE-ACS and PR-ACS, we draw blood from ACS patients for testing to assist in determining whether the ACS subtype is PE-ACS or PR-ACS.

Trial Locations (1)

200333

Tongji Hospital, Tongj University School of Medicine, 200333, Shanghai ,China, Shanghai

All Listed Sponsors
lead

Xuebo Liu

OTHER